Tests an egg powder with antisecretory factor in newly diagnosed glioblastoma
Compares an egg powder enriched with antisecretory factor against placebo in adults with glioblastoma.
Plain-language title generated from the registry record
Registry title: Antisecretory Factor Glioblastoma Phase 2
Key facts
- Where
- Lund, SwedenSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05669820, who can take part
Where in Sweden
- Skåne University HospitalLund, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peter Siesjö
- Trial code
- NCT05669820
- Record updated
- 9 January 2026
- Original description
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosisRead full original descriptionShow less
Antisecretory Factor During Concomitant and Adjuvant Therapy of Primary Glioblastoma, a Randomised, Prospective and Double Blinded Study
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Inclusion: Pathology verified glioblastoma or astrocytoma grade 4; Age 18-75 years; Surgical treatment-resection; Scheduled concomitant radiochemotherapy, or only chemotherapy; Informed consent.
Exclusion: Only surgical biopsy; Only radiotherapy; Egg yolk allergy; No informed consent.